AI Image
Off-Label Use of Ozempic-Style Drugs Is Surging
Newser • • health
Key Points:
- A new study analyzing records of over 92 million US adults found that more than 1.1 million people are using GLP-1 weight-loss drugs without documented conditions like obesity or diabetes, indicating off-label use has increased 15-fold from 2021 to 2025.
- Researchers suggest that many off-label users may not be obese but are seeking to lose modest amounts of weight, although the study did not specify users' reasons for taking the medications.
- The drugs, originally designed for weight loss and diabetes, are now being investigated for a wide range of other potential uses including endometriosis, Crohn's disease, depression, and longevity.
- A concerning finding is that off-label users are more likely to have a history of eating disorders, raising questions about the safety and long-term effects of widespread off-label use.
- Experts describe the situation as a "big Ozempic experiment," emphasizing uncertainty about the outcomes and the need for further research on the implications of this trend.
